GCMS
More information
WebinarsAbout usContact usTerms of use
LabRulez s.r.o. All rights reserved. Content available under a CC BY-SA 4.0 Attribution-ShareAlike

Nitrosamine impurities analysis solution guide

Guides | 2021 | Thermo Fisher ScientificInstrumentation
GC/MSD, GC/MS/MS, GC/HRMS, GC/QQQ, GC/Orbitrap, Ion chromatography, LC/HRMS, LC/MS, LC/MS/MS, LC/Orbitrap, LC/QQQ
Industries
Pharma & Biopharma
Manufacturer
Thermo Fisher Scientific

Summary

Significance of the Topic


Nitrosamine impurities are recognized as probable human carcinogens and have been detected in pharmaceutical products such as Valsartan, leading to global recalls. Their formation from nitrites and secondary amines during API synthesis and storage poses a critical safety risk. Robust analytical solutions are therefore essential to ensure patient safety, regulatory compliance, and to prevent costly product withdrawals.

Objectives and Overview


This guide presents a comprehensive strategy for nitrosamine impurity analysis throughout drug development and production. It compares liquid chromatography, gas chromatography, and ion chromatography methods coupled with high resolution accurate mass spectrometry (HRAM MS) and tandem mass spectrometry (MS/MS). The workflow emphasizes sensitivity, selectivity, throughput, and alignment with ICH M7(R1), FDA, and other global regulatory guidelines.

Methodology and Used Instrumentation


Analytical stages include:
  • Monitoring nitrite and amine precursors by ion chromatography with Reagent-Free eluent generation and UV detection.
  • High-throughput targeted screening using LC-MS/MS and GC-MS/MS on triple quadrupole platforms.
  • Exploratory and confirmatory analysis using LC-HRAM MS and GC-HRAM MS to eliminate false positives and provide exact mass confirmation.

Used Instrumentation


  • Vanquish Flex UHPLC, Vanquish Core HPLC, Acclaim PAII columns
  • TraceGOLD TG-1701 GC columns, TriPlus RSH autosampler
  • Orbitrap Exploris 120 LC-HRAM MS, Q Exactive Plus MS
  • Orbitrap Exploris GC-HRAM MS
  • TSQ Quantis, TSQ Altis, TSQ Fortis, TSQ 9000 triple quadrupole MS/MS
  • Dionex ICS-6000 HPIC system, IonPac AS19-4µm column
  • Chromeleon Chromatography Data System for instrument control, data analysis, and compliance-ready reporting

Main Results and Discussion


  • LC-HRAM MS at 120 000 resolution distinguished NDMA from DMF isotopes, preventing false positives and enabling low-ng/mL quantitation.
  • GC-HRAM MS achieved rapid separation of fifteen nitrosamines in under 12 minutes, with detection limits below 2 ppb and stable performance over two weeks.
  • LC-MS/MS methods delivered LOQs of 5 ppb (APCI) and 10 ppb (HESI) for metformin, maintaining reproducibility across more than 1 000 injections.
  • GC-MS/MS workflows complied with FDA and CFDA standards for Valsartan analysis, using static headspace injection to simplify sample handling.
  • IC-UV analysis detected nitrite in ranitidine at an LOD of 0.918 µg/g, supporting proactive control of precursor levels.

Benefits and Practical Applications


  • Integrated screening and confirmatory workflows combine high throughput with definitive HRAM identification, reducing instrument bottlenecks.
  • Automation and single-platform software ensure traceable data management and regulatory compliance.
  • Cost-effective MS/MS screening maximizes productivity and reserves HRAM capacity for critical confirmatory tests.
  • Ion chromatography monitoring of nitrite precursors enables upstream risk mitigation before nitrosamine formation.

Future Trends and Applications


Emerging developments include:
  1. Real-time in-line monitoring of precursors and impurities during manufacturing.
  2. Machine learning-driven method optimization and predictive impurity formation models.
  3. Wider adoption of HRAM in routine QC as instrument costs decline and workflows simplify.
  4. Regulatory requirements expanding to additional nitrosamines and lower action limits, demanding even greater sensitivity.
  5. Portable and miniaturized MS systems for decentralized screening across the pharmaceutical supply chain.

Conclusion


A multi-technique analytical strategy that combines IC, LC-MS/MS, GC-MS/MS, and HRAM MS provides sensitive, reliable, and compliant monitoring of nitrosamine impurities. Automation and unified software platforms support efficient workflows, early detection of genotoxic compounds, and reduced risk of product recalls.

References


  • ICH M7(R1) Guidelines on assessment and control of DNA reactive (mutagenic) impurities.
  • IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.
  • FDA Guidance for Industry on Control of Nitrosamine Impurities in Human Drugs.
  • Thermo Fisher Scientific technical brochures and application notes on nitrosamine analysis.

Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.

Downloadable PDF for viewing
 

Similar PDF

Toggle
Featured nitrosamine solutions
Featured nitrosamine solutions
2021|Thermo Fisher Scientific|Others
Ingredient and product monitoring • Monitor nitrite and amine levels during manufacturing process and storage • Risk monitoring Ion ch romat o Routine Screening • Sensitive, high throughput assays • Complementary analysis • LC and GC- MS/MS graph y High…
Key words
metformin, metforminnitrosamine, nitrosaminevalsartan, valsartanquad, quadtriple, tripleranitidine, ranitidinedetermination, determinationresolution, resolutionnitrite, nitritenitrosamines, nitrosaminesimpurities, impuritiesrbitra, rbitrauadru, uadruhigh, highingredient
Overcoming the challenges of nitrosamine impurities in drugs
Overcoming the challenges of nitrosamine impurities in drugs
2020|Thermo Fisher Scientific|Technical notes
CASE STUDY 73263 Overcoming the challenges of nitrosamine impurities in drugs What pharmaceutical QA/QC laboratories need to know: Advanced GC-MS capabilities for cGMP nitrosamine testing Why we need to analyze nitrosamine impurities in drugs Unacceptable levels of nitrosamine impurities were…
Key words
min, minndma, ndmandea, ndeanitrosamine, nitrosamineneipa, neipatime, timetemperature, temperatureimpurities, impuritiesorbitrap, orbitrapmass, massaquisition, aquisitionexactive, exactivesource, sourcekpa, kpainjection
Overcoming the challenges of nitrosamine impurities in drugs
CASE STUDY 73263 Overcoming the challenges of nitrosamine impurities in drugs What pharmaceutical QA/QC laboratories need to know: Advanced GC-MS capabilities for cGMP nitrosamine testing Why we need to analyze nitrosamine impurities in drugs Unacceptable levels of nitrosamine impurities were…
Key words
min, minndma, ndmandea, ndeanitrosamine, nitrosamineneipa, neipatime, timetemperature, temperatureimpurities, impuritiesorbitrap, orbitrapaquisition, aquisitionmass, massexactive, exactivesource, sourcekpa, kpaloop
Nitrosamine Impurities Application Guide - Confidently Detect and Quantify Mutagenic Impurities in APIs and Drug Products
Nitrosamine Impurities Application Guide Confidently Detect and Quantify Mutagenic Impurities in APIs and Drug Products Sartan-Based Losartan Valsartan Candesartan Telmisartan Metformin Ranitidine Nitrosamines are formed by chemical reactions that occur during API manufacturing whether from starting materials, intermediates, reactants, reuse…
Key words
back, backndma, ndmaneipa, neipandea, ndeandipa, ndipafda, fdandba, ndbametformin, metforminnitrosamine, nitrosamineintroduction, introductionapi, apivalsartan, valsartanquant, quantbest, bestdichloromethan
Other projects
LCMS
ICPMS
Follow us
More information
WebinarsAbout usContact usTerms of use
LabRulez s.r.o. All rights reserved. Content available under a CC BY-SA 4.0 Attribution-ShareAlike